tbc-11251 has been researched along with Disease Models, Animal in 11 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 3 (27.27) | 29.6817 |
| 2010's | 5 (45.45) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Baelde, HJ; Danser, AHJ; de Vries, R; Garrelds, IM; Mirabito Colafella, KM; Montezano, AC; Neves, KB; Touyz, RM; Uijl, E; van den Meiracker, AH; van Veghel, R; Versmissen, J | 1 |
| Eräranta, A; Lakkisto, P; Mustonen, J; Niemelä, O; Paavonen, T; Pörsti, I; Tikkanen, I; Törmänen, S | 1 |
| Duthie, KM; Hadoke, PW; Ivy, JR; Kirkby, NS; Lim, WG; McShane, JF; Miller, E; Webb, DJ | 1 |
| Cheung, L; Cosgrove, D; Delimont, D; Dufek, B; Gratton, MA; Liu, S; Meehan, DT; Phillips, G; Song, W | 1 |
| Cosgrove, D; Delimont, D; Dufek, B; Gratton, MA; Meehan, DT; Phillips, G; Zallocchi, M | 1 |
| Brimioulle, S; Dewachter, C; Dewachter, L; Fesler, P; Franck, S; Hubloue, I; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B | 1 |
| Brimiouille, S; Fesler, P; Hubloue, I; Huez, S; Kerbaul, F; Naeije, R; Remmelink, M; Rondelet, B; Salmon, I; Vivian, GF | 1 |
| Arthur, AS; Helm, GA; Kassell, NF; Lee, KS; Louis, HG; Wanebo, JE; West, K | 1 |
| Block, N; Brock, TA; Chen, SJ; Chen, YF; Dixon, RA; Munsch, CL; Sherwood, SJ; Tilton, RG; Wu, C | 1 |
| Almany, DK; Crawford, FA; Davis, JN; Fary, DJ; Goldberg, AT; Hendrick, JW; Joffs, C; Spinale, FG; Walker, CA | 1 |
1 review(s) available for tbc-11251 and Disease Models, Animal
| Article | Year |
|---|---|
Systemic administration of the endothelin-A receptor antagonist TBC 11251 attenuates cerebral vasospasm after experimental subarachnoid hemorrhage: dose study and review of endothelin-based therapies in the literature on cerebral vasospasm.
Topics: Animals; Basilar Artery; Calcium Signaling; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Endothelin Receptor Antagonists; Endothelin-1; Infusions, Intravenous; Ischemic Attack, Transient; Isoxazoles; Male; Rabbits; Receptor, Endothelin A; Subarachnoid Hemorrhage; Thiophenes | 1998 |
1 trial(s) available for tbc-11251 and Disease Models, Animal
| Article | Year |
|---|---|
Endothelin receptor subtype A blockade selectively reduces pulmonary pressure after cardiopulmonary bypass.
Topics: Analysis of Variance; Animals; Cardiopulmonary Bypass; Disease Models, Animal; Endothelin-1; Hemodynamics; Hypertension, Pulmonary; Isoxazoles; Pulmonary Circulation; Receptors, Endothelin; Swine; Thiophenes; Vascular Resistance; Ventricular Function, Left | 2001 |
9 other study(ies) available for tbc-11251 and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Selective ETA vs. dual ETA/B receptor blockade for the prevention of sunitinib-induced hypertension and albuminuria in WKY rats.
Topics: Albuminuria; Animals; Antihypertensive Agents; Arteries; Blood Pressure; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Epoprostenol; Hypertension; Isoxazoles; Kidney; Male; Oxidative Stress; Pyrimidines; Rats, Inbred WKY; Receptor, Endothelin A; Receptor, Endothelin B; Signal Transduction; Sulfonamides; Sunitinib; Thiophenes | 2020 |
Endothelin A receptor blocker and calcimimetic in the adenine rat model of chronic renal insufficiency.
Topics: Adenine; Animals; Calcimimetic Agents; Cinacalcet; Disease Models, Animal; Endothelin A Receptor Antagonists; Isoxazoles; Male; Rats; Rats, Wistar; Renal Insufficiency, Chronic; Thiophenes | 2017 |
Selective endothelin A receptor antagonism with sitaxentan reduces neointimal lesion size in a mouse model of intraluminal injury.
Topics: Animals; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Femoral Artery; Isoxazoles; Male; Mice; Mice, Inbred C57BL; Muscle Contraction; Muscle, Smooth, Vascular; Myography; Neointima; Pyrrolidines; Thiophenes | 2015 |
Endothelin A receptor activation on mesangial cells initiates Alport glomerular disease.
Topics: Animals; Biomechanical Phenomena; Disease Models, Animal; Endothelial Cells; Endothelin Receptor Antagonists; Endothelin-1; Fluorescent Antibody Technique; Gene Knockdown Techniques; Glomerular Basement Membrane; Hypertension; Isoxazoles; Laminin; Mesangial Cells; Mice; Mice, Inbred C57BL; Nephritis, Hereditary; Podocytes; Proteinuria; Pseudopodia; Receptor, Endothelin A; RNA Interference; RNA, Small Interfering; Signal Transduction; Thiophenes; Up-Regulation | 2016 |
Endothelin-1 mediated induction of extracellular matrix genes in strial marginal cells underlies strial pathology in Alport mice.
Topics: Animals; Basement Membrane; Body Temperature; Capillaries; Cell Line; Collagen Type IV; Disease Models, Animal; Endothelin-1; Extracellular Matrix; Gene Expression Regulation; Hypoxia; Isoxazoles; Laminin; Mice; Nephritis, Hereditary; Oxidative Stress; Phenotype; Stria Vascularis; Thiophenes | 2016 |
Sildenafil added to sitaxsentan in overcirculation-induced pulmonary arterial hypertension.
Topics: Angiopoietin-1; Animals; Bone Morphogenetic Protein Receptors, Type II; Disease Models, Animal; Drug Therapy, Combination; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Isoxazoles; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Pulmonary Circulation; Purines; Sildenafil Citrate; Subclavian Artery; Sulfones; Thiophenes; Treatment Outcome | 2010 |
Sitaxsentan for the prevention of experimental shunt-induced pulmonary hypertension.
Topics: Anastomosis, Surgical; Angiopoietin-1; Animals; Bone Morphogenetic Protein Receptors; Brachiocephalic Trunk; Disease Models, Animal; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Isoxazoles; Pulmonary Artery; RNA, Messenger; Swine; Thiophenes | 2007 |
Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Endothelin Receptor Antagonists; Endothelin-1; Hypertension, Pulmonary; Hypertrophy; Hypoxia; Isoxazoles; Male; Monocrotaline; Oxygen; Rats; Rats, Sprague-Dawley; Receptor, Endothelin A; Thiophenes; Vasoconstriction; Weight Gain | 2000 |